AriBio said Wednesday that it has released the results of additional phase 2 analyses of AR1001, an oral treatment for Alzheimer's disease, at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) in Boston, Mass. The investigational drug is being tested in a global phase 3 clinical trial.The compa
Celltrion Healthcare has successfully secured a bid for cancer drug procurement held by the United Nations Development Programme (UNDP) and will supply Truxima (ingredient: rituximab) and Vegzelma (ingredient: bevacizumab).Truxima is a biosimilar referencing Biogen's Rituxan for treating blood cance
Bridge Biotherapeutics, a Korean drug development company, announced Tuesday that it has initiated patient dosing in a phase 1/2 clinical trial at Samsung Medical Center to evaluate the efficacy and safety of BBT-207, a fourth generation Epidermal Growth Factor Receptor (EGFR) inhibitor.BBT-207 is b
Curocell, a Korean CAR-T therapy maker, said it has set its final initial public offering (IPO) price at 20,000 won ($14.78), with the total offering amounting to 32 billion won.The company plans to invest the raised capital in the commercialization of its CD19 CAR-T (chimeric antigen receptor-T) th
Three Greek yogurt products, which include two private brand (PB) items available at GS25 convenience stores, have been suspended due to the detection of E. coli bacteria levels surpassing the standard.As per the Ministry of Food and Drug Safety (MFDS)'s food safety website, GS25's private brand (PB
"We expect the antibody-drug conjugate (ADC) market to grow significantly, which is why we are investing $80 million in an ADC capacity expansion at our Syracuse Plant in New York City. Upon completion in the fourth quarter of 2024, we will be able to start GMP production in the first quarter of 202
Samsung Bioepis said Thursday that the company has won “Company of the Year, Asia-Pacific” and “Regulatory Achievement of the Year” awards at the Global Generics & Biosimilars (GGB) Awards 2023.The GGB Awards is an annual event organized by Citeline, an international publishing company, to recognize
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- GI Innovation has unveiled the phase 1/2 clinical trial results of its immunotherapy candidate, GI-101. Professor Cho Byoung-chul, head of the lung cancer center at Yonsei Cancer Center, presented the clinical results that GI-101 sh
Lunit said Tuesday that the result of applying the AI-based Lunit Scope as an exploratory biomarker in phase 3 immunotherapy-chemotherapy combination study in patients with genetically altered non-small cell lung cancer (NSCLC) has been published in the Journal of Clinical Oncology (JCO).JCO is the
For the first time since its inception, Samsung Biologics' quarterly sales exceeded 1 trillion won ($740.7 million) in the third quarter, thanks to an increase in sales from the operation of its fourth factory and improved operational efficiency.Samsung Biologics announced Wednesday a consolidated r
Recognizing Takeda's Entyvio as an official rival of Celltrion's Zymfentra, Celltrion Group Chairman Seo Jung-jin unveiled the company's plans to conduct a head-to-head comparison study.Speaking at a press conference to discuss the recent approval of the company's merger by shareholders on Wednesday
Samsung Biologics, a Korean contract development and manufacturing organization (CDMO), announced its partnership with Kurma Partners, a global biohealthcare venture capital firm, on Tuesday. This collaboration aims to provide support for the development and production of biopharmaceuticals for inve
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- At the European Society for Medical Oncology Annual Meeting (ESMO 2023), one of the world's top three cancer societies, Korean biotech companies, including Lunit, Medpacto, and TiumBio, highlighted their research achievements throug
The proposed merger between Celltrion and Celltrion Healthcare gained overwhelming approval from their respective shareholders on Monday.During an extraordinary general meeting at Songdo Convensia, Incheon, Celltrion secured a 97.04 percent approval rate for the merger contract. Similarly, Celltrion
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- The annual congress of the European Society for Medical Oncology (ESMO), Europe's largest cancer society, has been underway in Madrid, Spain, since Friday.As Korean visitors walk through the halls filled with promotional booths for
Curocell announced that it has concluded the phase 2 clinical trials of its CAR-T (chimeric antigen receptor-T) drug, Anbal-cel, for treating diffuse large B-cell lymphoma (DLBCL) as it recently completed administering the treatment to the final patient.Speaking at a press conference on Friday notif
"Reasons are aplenty for biopharmaceutical companies to invest in Uijeongbu. For instance, the city's proximity to Seoul makes it easy to attract high-quality human resources, the presence of university hospitals nearby facilitates the conduct of clinical trials, and the ability to purchase large pa
GC Cells said it has simultaneously filed a phase I IND for AB-201, an allogeneic chimeric antigen receptor-natural killer (CAR-NK) cell therapy targeting solid tumors, with the Ministry of Food and Drug Safety and the Australian Human Research Ethics Committee (HREC).The trial is the first human cl
3billion, an AI-powered genetic diagnostics company for rare diseases, has introduced the NovaSeq X, Illumina's next-generation sequencer.The NovaSeq X, succeeding the NovaSeq 6000, provides a substantial enhancement, offering up to 2.5 times the DNA sequencing capacity per run when compared to its
Sillajen said Monday that it has presented a poster on the clinical study of BAL0891, an anticancer drug undergoing phase I clinical trials in the U.S. and Korea, at the 2023 EORTC-NCI-AACR Symposium, which opened in Boston, Mass.The EORTC-NCI-AACR Symposium is an international conference jointly or